Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Lung Neoplasms 39Carcinoma, Hepatocellular 38Small Cell Lung Carcinoma 26Breast Neoplasms 19Neoplasms 18Cholangiocarcinoma 18Urinary Bladder Neoplasms 17Colorectal Neoplasms 15Triple Negative Breast Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Pancreatic Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Recurrence 9Ovarian Neoplasms 9Neoplasm Metastasis 9Esophageal Neoplasms 8Carcinoma, Renal Cell 8Stomach Neoplasms 7Head and Neck Neoplasms 7Carcinoma, Transitional Cell 7Prostatic Neoplasms 6Melanoma 6Endometrial Neoplasms 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Neoplasms by Site 5Mesothelioma, Malignant 5Adenocarcinoma 5

Interventions

durvalumab 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced or Metastatic Solid Tumours × durvalumab × Clear all
NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

AstraZeneca

Phase 2 Active not recruiting
126 enrolled 30 charts
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡